Recent Updates
Recently added Catalysts
MYGN Positive Sentiment

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

Key Takeaway: Myriad Genetics, Inc. (NASDAQ: MYGN) will release its third quarter financial results on November 6, 2023, followed by an earnings conference call at 4:30 p.m. EDT. The company aims to offer a financial overview and business update during the call. Participants can access the conference through several dial-in and webcast options, fostering investor communication.
Price reaction · baseline $14.48 (2023-10-30 close) · hit after-hours · 1 other MYGN headline(s) in the window, move may be shared
day 0 close
+7.6%
day 1
+8.7%
day 3 · peak
+17.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Myriad Genetics is a leader in genetic testing and precision medicine.
  • The upcoming earnings call will provide insights into the company's performance.
  • The conference call highlights transparency and engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~41 mo
Minimal dilution risk
Lead asset
SKB264
Phase 2 · Solid Tumor

Full Press Release Details

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the same day after the market closes.
During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2023.
Conference Call and Webcast
The dial-in number for domestic callers is 1-800-771-6781. International callers may dial 1-212-231-2900. All callers will be asked to reference reservation number 22028316. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call and slide presentation will be available through a live webcast at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Media Contact: Investor Contact:
Glenn Farrell Matt Scalo
(385) 318-3718 (801) 584-3532
PR@myriad.com IR@myriad.com

Frequently Asked Questions

When is Myriad Genetics' Q3 earnings call scheduled?

The earnings call is on November 6, 2023, at 4:30 p.m. EDT.

How can I access the earnings call webcast?

The webcast can be accessed at www.myriad.com.

What will be discussed during the earnings call?

Myriad management will review financials and business updates for Q3 2023.

What is Myriad Genetics known for?

Myriad Genetics specializes in genetic testing and precision medicine.

How can I listen to the archived call?

Call 1-800-633-8284 and enter reservation number 22028316.

Last updated: Oct 31, 2023